Among IRF2 targets were the inhibitors of inflammation myocyte enhancer factor 2C (MEF2C) and annexin A1, (ANXA1, also known as lipocortin 1), which was recently shown to decrease atherosclerosis in a mouse model [13–15]. The gene discussed is MEF2C; the disease is atherosclerosis.